<- Go Home
Allakos Inc.
Allakos Inc. operates as a clinical stage biotechnology company that develops monoclonal antibodies that target immunomodulatory receptors present on the surface of immune effector cells involved in allergy, inflammatory, and proliferative diseases. The company was incorporated in 2012 and is based in San Carlos, California. As of May 15, 2025, Allakos Inc. operates as a subsidiary of Concentra Biosciences, LLC.
Market Cap
$29.7M
Volume
1.0M
Cash and Equivalents
$24.2M
EBITDA
-$84.9M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
N/A
Profit Margin
N/A
52 Week High
$1.55
52 Week Low
$0.22
Dividend
N/A
Price / Book Value
0.54
Price / Earnings
-0.41
Price / Tangible Book Value
0.54
Enterprise Value
-$25.5M
Enterprise Value / EBITDA
0.30
Operating Income
-$99.7M
Return on Equity
88.87%
Return on Assets
-52.64
Cash and Short Term Investments
$55.2M
Debt
N/A
Equity
$55.5M
Revenue
N/A
Unlevered FCF
-$48.8M
Sector
Biotechnology
Category
N/A